Alluvi, formerly BI 4744, offers a promising development in weight loss therapy. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in research studies, potentially surpassing https://worldsocialindex.com/story7239012/alluvi-a-detailed-investigation-into-retatrutide-s-potential